Aegerion Pharma Reserves Shares for Inducement Stock Options

Aegerion Pharmaceuticals,Inc. (Nasdaq: AEGR), an emerging biopharmaceutical company focused on thedevelopment and commercialization of novel therapeutics to treat debilitatingand often fatal rare diseases, today announced that, in support of Aegerion'sbuild of its U.S. commercial organization and international expansion, theCompensation Committee of the Company's Board of Directors has approved thereservation of 1,000,000 shares of common stock to be used exclusively for thegrant of non-qualified stock options to individuals who were not previously anemployee or non-employee director of Aegerion (or following a bona fide periodof non-employment), as an inducement new hire stock option award material toan individual's entry into employment within the meaning of Rule 5635(c)(4) ofthe NASDAQ Listing Rules (Inducement Stock Options).     On December 3, 2012, Aegerion granted stock options to purchase an aggregateof 218,600 shares of common stock to 23 new employees under the inducementgrant program.  Each stock option has an exercise price per share equal to$21.55, the closing price of Aegerion's common stock on the grant date, andvests in equal monthly installments over four years. Each stock option has aten year term and will be subject to the terms and conditions of a stockoption agreement covering the grant.